Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.
You may also be interested in...
As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results
Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.
Analysts Weigh Gilead’s Future In HIV
Despite recent sell-off on R&D cost worries, competitors’ patent expiry and safety issues could help.
Analysts Weigh Gilead’s Future In HIV
Despite recent sell-off on R&D cost worries, competitors’ patent expiry and safety issues could help.